Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC™s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARD OBTAINS BALLOON-EXPANDABLE CORONARY STENT THROUGH ACQUISITION OF CONTROLLING STAKE IN X-TRODE; FIRM PLANNING PROSTATE CANCER TEST LAUNCHES

This article was originally published in The Gray Sheet

Executive Summary

Bard is gaining its second coronary stent franchise through the purchase of a majority stake in X-Trode, a Bologna, Italy-based company developing a balloon-expandable stainless steel stent.

You may also be interested in...



Fragrance Creators Association Launches Online ‘Conservatory’ To Bolster Consumer Confidence

The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.

Vemedia Acquires GSK Brands In Italy, Strikes Deal For GI Product In Spain

GSK has offloaded a further two brands, this time in Italy, giving Netherlands-based Vemedia the opportunity to bolster its portfolio in the country. Vemedia has also added to its offering in Spain by striking a separate deal with Puerto Galiano.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

UsernamePublicRestriction

Register

MT005467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel